PROCEPT BioRobotics Sales Rise 18% To $98.3 Million, But Quarterly Loss Widens To $26.5 Million

Procedures climbed about 22% in the third quarter, yet U.S. system sales were flat and the company held its 2026 outlook.

Share
PROCEPT BioRobotics Sales Rise 18% To $98.3 Million, But Quarterly Loss Widens To $26.5 Million

PROCEPT BioRobotics, which makes robotic systems for urologic surgery, said Wednesday its third-quarter revenue rose 18% to $98.3 million while its net loss widened to $26.5 million from $21.4 million a year earlier. The company reiterated its full-year 2026 guidance.

Spending outruns sales

Operating expenses reached $92.5 million, against $77.2 million in the prior-year quarter. The company said the increase reflects continued investment in people, product development, clinical studies and sales and marketing. Adjusted EBITDA, which excludes interest, taxes, depreciation, amortization and stock pay, was a loss of $9.8 million, compared with a $7.4 million loss a year earlier.

Gross margin was 66%, up from 65%. Net loss per share was $0.46, versus $0.38.

Cash and cash equivalents fell to $218.4 million at September 30 from $286.5 million at the end of 2025, according to the balance sheet.

Handpieces carry the growth

PROCEPT sells the AquaBeam and HYDROS robots, which deliver Aquablation, a heat-free waterjet therapy for an enlarged prostate. Each procedure uses a single-use handpiece, so repeat surgeries drive much of the revenue.

U.S. procedures topped 13,400, up about 22%. U.S. handpiece and consumable revenue rose 21% to $53.9 million, and the handpiece average selling price of about $3,570 was up 12% from a year earlier. U.S. system revenue, by contrast, was flat at $24.7 million.

The company delivered 62 U.S. HYDROS systems, 20 of them replacements for AquaBeam units, at an average price of about $495,000 for new systems. U.S. revenue was $85.8 million, up 16%, and international revenue rose 32% to $12.5 million.

Guidance held, cancer data due

Management reiterated 2026 revenue of $390 million to $410 million, U.S. procedures of 54,000 to 56,000, gross margin of about 65% and an adjusted EBITDA loss of $35 million to $30 million.

CEO Larry Wood said the company remains focused on its full-year revenue guidance and profitability plan. He said data from WATER IV, a randomized trial comparing Aquablation with radical prostatectomy in prostate cancer, is on track for the first half of 2027.

The company hosts its earnings call Wednesday at 4:30 p.m. Eastern.

Sources

More on PROCEPT BioRobotics

All PROCEPT BioRobotics (PRCT) coverage →